Frequently Asked Questions
The global blood coagulation testing market was valued at USD 3945.5 Million in 2022.
The blood coagulation testing market is expected to grow at a CAGR of 11.9% between 2023 and 2030, reaching USD 9699.35 Million in 2030.
Thrombin time (TT) tests are the leading segment by test type, holding over 25% share in value in 2022.
The hemophilia segment governs the global demand for blood coagulation testing, holding a massive share of over 30% in 2022.
The electrochemical technology segment will post the highest CAGR over the projection period.
With more than one-third of the market in 2022, North America is driving the expansion of the blood coagulation testing industry.
The top players include Thermo Fisher Scientific Inc, Micropoint Biosciences, Medtronic, Helena Laboratories Corporation, F. Hoffmann-La Roche Ltd, Sysmex Corporation, Nihon Kohden Corporation, Abbott, BD, Danaher Corporation, and Others.
Major market drivers of the blood coagulation testing industry include the increasing prevalence of hemostatic disorders and advancements in diagnostic technologies.
Major market restraints of the blood coagulation testing industry include the high cost of testing products and limited awareness and education among healthcare professionals and patients.
Major market opportunities in the blood coagulation testing industry include the rising demand for point-of-care testing and the potential for personalized medicine and targeted therapies.